FDA adds boxed warning to Teva’s Copaxone for allergic reaction

The Food and Drug Administration is adding a boxed warning about the risk of an allergic reaction for Teva‘s (TEVA) Copaxone and Sandoz’s (SDZNY) Glatopa, which are used to treat patients with multiple sclerosis. A serious allergic reaction, called anaphylaxis, can occur at any time while on treatment, after the first dose or after doses administered months or years after starting the medicine, the agency said in a statement.